Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body.[1] The antibody modified liposomes target tissue through cell-specific antibodies with the release of drugs contained within the assimilated liposomes.[1] Immunoliposome aims to improve drug stability, personalize treatments, and increased drug efficacy.[1] This form of therapy has been used to target specific cells, protecting the encapsulated drugs from degradation in order to enhance their stability, to facilitate sustained drug release and hence to advance current traditional cancer treatment.[1]